These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

600 related articles for article (PubMed ID: 27932374)

  • 1. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study.
    Rea D; Nicolini FE; Tulliez M; Guilhot F; Guilhot J; Guerci-Bresler A; Gardembas M; Coiteux V; Guillerm G; Legros L; Etienne G; Pignon JM; Villemagne B; Escoffre-Barbe M; Ianotto JC; Charbonnier A; Johnson-Ansah H; Noel MP; Rousselot P; Mahon FX;
    Blood; 2017 Feb; 129(7):846-854. PubMed ID: 27932374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial.
    Clark RE; Polydoros F; Apperley JF; Milojkovic D; Rothwell K; Pocock C; Byrne J; de Lavallade H; Osborne W; Robinson L; O'Brien SG; Read L; Foroni L; Copland M
    Lancet Haematol; 2019 Jul; 6(7):e375-e383. PubMed ID: 31201085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study.
    Mahon FX; Boquimpani C; Kim DW; Benyamini N; Clementino NCD; Shuvaev V; Ailawadhi S; Lipton JH; Turkina AG; De Paz R; Moiraghi B; Nicolini FE; Dengler J; Sacha T; Takahashi N; Fellague-Chebra R; Acharya S; Wong S; Jin Y; Hughes TP
    Ann Intern Med; 2018 Apr; 168(7):461-470. PubMed ID: 29459949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.
    Saussele S; Richter J; Guilhot J; Gruber FX; Hjorth-Hansen H; Almeida A; Janssen JJWM; Mayer J; Koskenvesa P; Panayiotidis P; Olsson-Strömberg U; Martinez-Lopez J; Rousselot P; Vestergaard H; Ehrencrona H; Kairisto V; Machová Poláková K; Müller MC; Mustjoki S; Berger MG; Fabarius A; Hofmann WK; Hochhaus A; Pfirrmann M; Mahon FX;
    Lancet Oncol; 2018 Jun; 19(6):747-757. PubMed ID: 29735299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial.
    Clark RE; Polydoros F; Apperley JF; Milojkovic D; Pocock C; Smith G; Byrne JL; de Lavallade H; O'Brien SG; Coffey T; Foroni L; Copland M
    Lancet Haematol; 2017 Jul; 4(7):e310-e316. PubMed ID: 28566209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Analysis of the efficacy and influencing factors of nilotinib or dasatinib as second- or third-line treatment in patients with chronic myeloid leukemia in the chronic phase and accelerated phase].
    Yuan T; Lai YY; Qin YZ; Shi HX; Huang XJ; Hou Y; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2020 Feb; 41(2):93-99. PubMed ID: 32135623
    [No Abstract]   [Full Text] [Related]  

  • 7. Final report of TKI discontinuation trial with dasatinib for the second attempt of treatment-free remission after failing the first attempt with imatinib: Treatment-free Remission Accomplished by Dasatinib (TRAD) study.
    Perusini MA; Novitzky-Basso I; Atenafu EG; Forrest D; Bence-Bruckler I; Savoie L; Keating MM; Busque L; Delage R; Xenocostas A; Liew E; Laneuville P; Paulson K; Stockley T; Lipton JH; Leber B; Kim DDH
    Br J Haematol; 2023 Dec; 203(5):781-791. PubMed ID: 37697469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
    Kong JH; Winton EF; Heffner LT; Chen Z; Langston AA; Hill B; Arellano M; El-Rassi F; Kim A; Jillella A; Kota VK; Bodó I; Khoury HJ
    Cancer; 2017 Jul; 123(13):2482-2488. PubMed ID: 28241101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
    Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J
    Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment-free remission with first- and second-generation tyrosine kinase inhibitors.
    Cortes J; Rea D; Lipton JH
    Am J Hematol; 2019 Mar; 94(3):346-357. PubMed ID: 30394563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Observational study of chronic myeloid leukemia Chinese patients who discontinued tyrosine kinase inhibitors in the real-world].
    Zhao HF; Yang YF; Liu BC; Li WM; Xu N; Liu XL; Jiang Q; Dang HB; Liang LX; Zhang Y; Song YP
    Zhonghua Xue Ye Xue Za Zhi; 2022 Aug; 43(8):636-643. PubMed ID: 36709147
    [No Abstract]   [Full Text] [Related]  

  • 12. Adherence and persistence among chronic myeloid leukemia patients during second-line tyrosine kinase inhibitor treatment.
    Trivedi D; Landsman-Blumberg P; Darkow T; Smith D; McMorrow D; Mullins CD
    J Manag Care Spec Pharm; 2014 Oct; 20(10):1006-15. PubMed ID: 25278323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nilotinib vs dasatinib in achieving MR4.5 for de novo chronic myeloid leukemia: the randomized JALSG CML212 study.
    Matsumura I; Ohtake S; Atsuta Y; Kurata M; Minami Y; Takahashi N; Nakaseko C; Iriyama N; Fujimaki K; Kakihana K; Ogasawara Y; Ono T; Okada M; Tauchi T; Miyamoto T; Ohnishi K; Sakaida E; Fujisawa S; Kobayashi Y; Asou N; Naoe T; Kiyoi H; Miyazaki Y
    Blood Adv; 2024 Oct; 8(20):5237-5247. PubMed ID: 38968156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial.
    Atallah E; Schiffer CA; Radich JP; Weinfurt KP; Zhang MJ; Pinilla-Ibarz J; Kota V; Larson RA; Moore JO; Mauro MJ; Deininger MWN; Thompson JE; Oehler VG; Wadleigh M; Shah NP; Ritchie EK; Silver RT; Cortes J; Lin L; Visotcky A; Baim A; Harrell J; Helton B; Horowitz M; Flynn KE
    JAMA Oncol; 2021 Jan; 7(1):42-50. PubMed ID: 33180106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world therapeutic response and tyrosine kinase inhibitor discontinuation in chronic phase-chronic myeloid leukemia: data from the French observatory.
    Saugues S; Lambert C; Daguenet E; Ansah HJ; Turhan A; Huguet F; Guerci-Bresler A; Tchirkov A; Hamroun D; Hermet E; Pereira B; Berger MG
    Ann Hematol; 2022 Oct; 101(10):2241-2255. PubMed ID: 36040480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors.
    Falchi L; Kantarjian HM; Wang X; Verma D; Quintás-Cardama A; O'Brien S; Jabbour EJ; Ravandi-Kashani F; Borthakur G; Garcia-Manero G; Verstovsek S; Burger JA; Luthra R; Cortes JE
    Am J Hematol; 2013 Dec; 88(12):1024-9. PubMed ID: 23913852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
    Shiseki M; Yoshida C; Takezako N; Ohwada A; Kumagai T; Nishiwaki K; Horikoshi A; Fukuda T; Takano H; Kouzai Y; Tanaka J; Morita S; Sakamoto J; Sakamaki H; Inokuchi K
    Int J Clin Oncol; 2017 Oct; 22(5):972-979. PubMed ID: 28550414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment.
    Okada M; Imagawa J; Tanaka H; Nakamae H; Hino M; Murai K; Ishida Y; Kumagai T; Sato S; Ohashi K; Sakamaki H; Wakita H; Uoshima N; Nakagawa Y; Minami Y; Ogasawara M; Takeoka T; Akasaka H; Utsumi T; Uike N; Sato T; Ando S; Usuki K; Mizuta S; Hashino S; Nomura T; Shikami M; Fukutani H; Ohe Y; Kosugi H; Shibayama H; Maeda Y; Fukushima T; Yamazaki H; Tsubaki K; Kukita T; Adachi Y; Nataduka T; Sakoda H; Yokoyama H; Okamoto T; Shirasugi Y; Onishi Y; Nohgawa M; Yoshihara S; Morita S; Sakamoto J; Kimura S;
    Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):353-360.e1. PubMed ID: 29610029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.
    Rousselot P; Charbonnier A; Cony-Makhoul P; Agape P; Nicolini FE; Varet B; Gardembas M; Etienne G; Réa D; Roy L; Escoffre-Barbe M; Guerci-Bresler A; Tulliez M; Prost S; Spentchian M; Cayuela JM; Reiffers J; Chomel JC; Turhan A; Guilhot J; Guilhot F; Mahon FX
    J Clin Oncol; 2014 Feb; 32(5):424-30. PubMed ID: 24323036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The initial molecular response predicts the deep molecular response but not treatment-free remission maintenance in a real-world chronic myeloid leukemia cohort.
    Saugues S; Lambert C; Daguenet E; Roth-Guepin G; Huguet F; Cony-Makhoul P; Ansah HJ; Escoffre-Barbe M; Turhan A; Rousselot P; Tchirkov A; Hamroun D; Hermet E; Pereira B; Berger MG
    Haematologica; 2024 Sep; 109(9):2893-2907. PubMed ID: 38695126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.